About Us
Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.
What we do
Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.
Our primary goals encompass pioneering advancements in biotechnology to develop groundbreaking therapies and diagnostic tools.
We aim to address unmet medical needs in diverse areas such as oncology, neurology, infectious diseases, and rare genetic disorders.
a future free from toxic chemo- therapy
Our goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
Our latest news
September 19, 2024
PersonalAIze and Cube Forge Groundbreaking Partnership
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes.
September 17, 2024
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform
Assessment by specialist Ai team from “PersonalAIze” Highlights the Strenght, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform.
September 13, 2024
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
September 11, 2024
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of Cube, currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB.
